AACR Annual Meeting 2019: New Approaches to Treating Drug-resistant Non-small Cell Lung Cancer
About 80 percent of lung cancers are non-small cell lung cancers (NSCLC), and about 15 to 20 percent of...
Tag: Lung cancer
About 80 percent of lung cancers are non-small cell lung cancers (NSCLC), and about 15 to 20 percent of...
Wen-Yang Lin, PhD, MS, currently a postdoctoral fellow at Stanford University and the recipient of the 2017 AACR-Genentech Fellowship...
The lung cancer death rate—the number of lung cancer deaths per 100,000 U.S. men and women—has been decreasing slowly...
The past month has seen the U.S. Food and Drug Administration (FDA) expand the use of four anticancer therapeutics,...
Monday ushered in a ray of hope and promise for the lung cancer community at the AACR Annual Meeting...
The U.S. Food and Drug Administration (FDA) recently approved expanding the use of the immunotherapeutic durvalumab (Imfinzi) to include...
A diverse group of about 220 physicians, patient advocates, and scientists in basic, translational, and clinical lung cancer research...
Much has been written, including on this blog, about the rapidly expanding use of immunotherapy to treat an increasing...
Cigarette smoking is the leading cause of death from lung cancer in the United States. That’s why November, Lung...
Hot on the heels of the FDA’s landmark approval of an anticancer therapeutic for use based on whether a...